{"id":"W2309303154","doi":"10.1093/annonc/mdu342.5","title":"Nivolumab (N) (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Sunitinib (S) or Pazopanib (P) in Patients (Pts) with Metastatic Renal Cell Carcinoma (Mrcc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Nivolumab; Renal cell carcinoma; Pazopanib; Adverse effect; Internal medicine; Sunitinib; Peripheral edema; Nausea; Oncology; Toxicity; Urology; Gastroenterology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004778201,0.0003506225,0.0009948574,0.0002282689,0.0002727926,0.0004516091,0.0003051414,0.000313748,0.001400995],"category_scores_gemma":[0.0005801243,0.0001827888,0.0006446486,0.0003837768,0.000200349,0.0003888312,0.000177896,0.0008289907,0.0002864791],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006758689,"about_ca_system_score_gemma":0.0009602302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001714867,"about_ca_topic_score_gemma":0.0104794,"domain_scores_codex":[0.9998358,0.00006173688,0.00001612951,0.00002665449,0.00002467219,0.00003492085],"domain_scores_gemma":[0.999846,0.00003104161,0.00002593253,0.000004560905,0.000009862027,0.00008256366],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2318061,0.006177638,0.1211117,0.002311736,0.003120296,0.001934482,0.0005181557,0.005673722,0.04362691,0.0005200498,0.01499691,0.5682024],"study_design_scores_gemma":[0.1110838,0.2139216,0.5574532,0.0006678193,0.007859329,0.009263702,0.001015955,0.01472345,0.02360083,0.001646371,0.05858577,0.0001781881],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841852,0.009826086,0.0001972607,0.0006280558,0.0001842751,0.0001587748,0.0003240619,0.00005925952,0.004437095],"genre_scores_gemma":[0.9958786,0.002372757,0.0003650193,0.0001884004,0.00008067661,0.00004724094,0.0002905839,0.000006219967,0.0007704701],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001714867,"threshold_uncertainty_score":0.004903793,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05448041269627978,"score_gpt":0.3114101677867561,"score_spread":0.2569297550904763,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}